Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
January 13, 2015 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 13, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results when...
Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
January 06, 2015 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 6, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results...
Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
December 17, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Dec 17, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
November 24, 2014 16:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 24, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
November 18, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 18, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device™, announced that an independent...
Arch Therapeutics Will Present at Two Investor Conferences in November
November 10, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin
November 06, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 6, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device ™, announced that an independent...
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
October 23, 2014 08:15 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced today that it is...
Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014
September 30, 2014 08:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 30, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced that it will be featured as a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29
September 23, 2014 08:50 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in...